|1.||Edvinsson, L: 1 article (03/2001)|
|2.||Goadsby, P J: 1 article (03/2001)|
|3.||Knight, Y E: 1 article (03/2001)|
|1.||Migraine Disorders (Migraine)
03/01/2001 - "Given that 4991W93 is inactive clinically at non-vascular doses, it seems clear that the 5HT(1B/1D) agonist effects of the compound are necessary for blockade of CGRP release and thus any anti-migraine action. "
03/01/2001 - "4991W93, a conformationally restricted analogue of zolmitriptan, is also a potent inhibitor of PPE at doses without 5HT(1B/1D)-mediated effects, that was developed as an anti-migraine drug, and thus was suitable to test whether higher doses of such conformationally restricted triptan analogues could inhibit trigeminal-evoked CGRP release. "